clinical trial · NCT03522246
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Epithelial Ovarian CancerPrimary PeritonealFallopian Tube CancerNewly DiagnosedFIGO Stage III-IVPartial ResponseComplete ResponseRucaparibNivolumabPlacebo Oral TabletPlacebo IV Infusion
brief summary
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
started
May 14, 2018
primary completion
May 20, 2024
completion
Dec 30, 2030
last updated
Jun 24, 2025
official title
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol